Microginon (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol provides estrogenic activity while levonorgestrel supplies progestogenic effects. Together they suppress the hypothalamic‑pituitary‑gonadal axis, preventing the surge of luteinising hormone and follicle‑stimulating hormone needed for ovulation. The progestin also thickens cervical mucus and makes the uterine lining less suitable for implantation.

The specific dosing regimen for Microginon is determined by the prescribing healthcare professional. Typically, a combined oral contraceptive is taken as one tablet daily at the same time each day, but the exact schedule and any missed‑dose instructions are provided by the prescriber.

Microginon is not intended for use during pregnancy and should be discontinued if pregnancy occurs. While some combined oral contraceptives are considered compatible with breastfeeding after the first six weeks postpartum, the prescriber will evaluate individual risk‑benefit factors before recommending use during lactation.

To order Microginon, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any required temperature control) and assist with import documentation.

Microginon contains the widely used dose combination of ethinylestradiol and levonorgestrel, offering a balance of efficacy and tolerability comparable to other second‑generation combined pills. Compared with newer formulations that may use different progestins, Microginon’s profile is well‑characterised, making it a reliable option for most women when contraindications are absent.

Microginon tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture, heat and direct sunlight, and keep out of reach of children.

Microginon is taken orally with a glass of water, usually once daily at the same time each day. It is important to follow the prescriber’s instructions regarding the start of a new pack and actions to take if a dose is missed.

The most serious risks include venous thromboembolism (deep‑vein thrombosis, pulmonary embolism), arterial events such as stroke or myocardial infarction, and rare severe allergic reactions. Women with a history of clotting disorders, uncontrolled hypertension, smoking over age 35, or estrogen‑dependent tumors should be evaluated carefully before use.

Microginon is contraindicated in women with known or suspected pregnancy, active or history of thromboembolic disease, uncontrolled hypertension, certain estrogen‑dependent cancers, severe liver disease, or those who are breastfeeding within the first six weeks postpartum. It should also be avoided in smokers over 35 years of age unless an alternative method is chosen.